We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott Banks on FDA Approvals and Buyouts, Competition Rife
Read MoreHide Full Article
On Oct 12, we issued an updated research report on Abbott (ABT - Free Report) — a global healthcare company dedicated toward improving life through the development of products and technologies. The stock carries a Zacks Rank #3 (Hold).
Over the last three months, Abbott has been trading above the broader industry. The stock has gained 11.9% as against the industry's decline of 0.8%.
The market is upbeat about the several new initiatives adopted by Abbott. The latest buyout by the company is of Alere on Oct 3.
Abbott has also announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Moreover, the company announced the receipt of FDA approval for magnetic resonance (MR) conditional labeling for its Ellipse implantable cardioverter defibrillator (ICD).
Apart from FDA approvals and buyouts, we are upbeat about Abbott’s FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017. At this platform, the company announced Health Canada License for FreeStyle Libre in June 2017. Abbott also announced that the FreeStyle Libre system is now available for reimbursement in the U.K.
On the flip side, Abbott’s sluggish pediatric business in China continues to mar growth. Management is concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Also, foreign exchange is a major headwind for Abbott as a considerable portion of its revenues comes from outside the United States.
QIAGEN has a long-term expected earnings growth rate of 13.1%. The stock rallied roughly 26.8% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 45.6% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 27.5% last year.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Image: Bigstock
Abbott Banks on FDA Approvals and Buyouts, Competition Rife
On Oct 12, we issued an updated research report on Abbott (ABT - Free Report) — a global healthcare company dedicated toward improving life through the development of products and technologies. The stock carries a Zacks Rank #3 (Hold).
Over the last three months, Abbott has been trading above the broader industry. The stock has gained 11.9% as against the industry's decline of 0.8%.
The market is upbeat about the several new initiatives adopted by Abbott. The latest buyout by the company is of Alere on Oct 3.
Abbott has also announced the receipt of FDA approval for the FreeStyle Libre Flash glucose monitoring system in the United States. Moreover, the company announced the receipt of FDA approval for magnetic resonance (MR) conditional labeling for its Ellipse implantable cardioverter defibrillator (ICD).
Apart from FDA approvals and buyouts, we are upbeat about Abbott’s FreeStyle Libre Flash Glucose Monitoring System prospects post the receipt of full or partial reimbursement by the French Health Ministry in May 2017. At this platform, the company announced Health Canada License for FreeStyle Libre in June 2017. Abbott also announced that the FreeStyle Libre system is now available for reimbursement in the U.K.
On the flip side, Abbott’s sluggish pediatric business in China continues to mar growth. Management is concerned about the economic problems in Venezuela that are expected to remain unresolved for some time. Also, foreign exchange is a major headwind for Abbott as a considerable portion of its revenues comes from outside the United States.
Key Stocks
A few better-ranked stocks in the medical sector are QIAGEN (QGEN - Free Report) , IDEXX Laboratories, Inc. (IDXX - Free Report) and Thermo Fisher Scientific Inc. (TMO - Free Report) . QIAGEN, IDEXX Laboratories and Thermo Fisher carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
QIAGEN has a long-term expected earnings growth rate of 13.1%. The stock rallied roughly 26.8% last year.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock gained 45.6% last year.
Thermo Fisher has a long-term expected earnings growth rate of 11.7%. The stock gained 27.5% last year.
4 Stocks to Watch after the Massive Equifax Hack
Cybersecurity stocks spiked on recent news of a data breach affecting 143 million Americans. But which stocks are the best buy candidates right now? And what does the future hold for the cybersecurity industry?
Equifax is just the most recent victim. Computer hacking and identity theft are more common than ever. Zacks has just released Cybersecurity! An Investor’s Guide to inform Zacks.com readers about this $170 billion/year space. More importantly, it highlights 4 cybersecurity picks with strong profit potential.
Get the new Investing Guide now>>